New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
06:49 EDTLCI, ACT, MYL, TEVAGeneric drug prices have risen significantly, NY Times says
The cost of some generic drugs has risen rapidly since last year, according to The New York Times, which cited information from research firm EvaluatePharma. Publicly traded generic drug companies include Teva (TEVA), Mylan (MYL), Actavis (ACT) Impax Laboratories (IPXL), and Lannett (LCI). Reference Link
News For TEVA;MYL;ACT;LCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 8, 2015
13:07 EDTMYL, TEVAMylan bid for Perrigo makes strategic sense, says JPMorgan
Subscribe for More Information
13:03 EDTMYLPerrigo says board will meet to discuss Mylan proposal
Subscribe for More Information
12:37 EDTTEVATeva downgraded to Hold from Buy at Standpoint Research
Subscribe for More Information
12:17 EDTMYLOn The Fly: Midday Wrap
Subscribe for More Information
11:51 EDTMYLPerrigo calls active on Mylan proposal to acquire for $205 per share
Subscribe for More Information
11:45 EDTMYLMylan volatility up after proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:40 EDTMYLPerrigo up $47.10 to $211.81, trading above Mylan's $205/share proposal
Subscribe for More Information
11:35 EDTMYLGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
Subscribe for More Information
11:34 EDTMYLGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
11:32 EDTMYLMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:31 EDTMYLPerrigo halted for volatility after jumping 7% to $176.42
Subscribe for More Information
11:29 EDTMYLMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
09:16 EDTACTActavis COPD drug Daliresp gets Paragraph 4 challenge
Subscribe for More Information
08:05 EDTACTActavis price target raised to $348 from $328 at Leerink
Subscribe for More Information
08:04 EDTACTActavis potential acquisition Rhythm initiates Phase 2b study of relamorelin
Subscribe for More Information
07:34 EDTACTActavis initiates Phase 2b clinical trial of relamorelin
Subscribe for More Information
07:16 EDTTEVA, MYLMylan one of the cheapest names in Specialty Pharma, says JPMorgan
Subscribe for More Information
April 7, 2015
15:24 EDTTEVATeva price target raised to $75 from $64 at BMO Capital
BMO Capital raised its EPS estimates for Teva (TEVA) and increased its price target on the stock to $75 from $64 on account of the expected launch of a treatment for chorea associated with Huntington’s disease in 3Q16 and a launch of a tardive dyskinesia drug in 3Q17 following the company's deal to buy Auspex (ASPX). The firm maintains its Outperform rating on Teva shares.
10:19 EDTMYLHigh option volume stocks
Subscribe for More Information
07:32 EDTMYLMylan launches Norethindrone and Ethinyl Estradiol Tablets in U.S.
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use